Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) have been given a consensus rating of “Moderate Buy” by the thirteen analysts that are currently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, eleven have issued a buy rating and one has given a strong buy rating to the company. The average 12-month price target among brokers that have covered the stock in the last year is $10.4167.

TSHA has been the subject of several research reports. Raymond James Financial initiated coverage on shares of Taysha Gene Therapies in a research report on Tuesday, October 21st. They set a “strong-buy” rating and a $13.00 price target for the company. UBS Group set a $11.00 target price on shares of Taysha Gene Therapies in a research report on Thursday, December 4th. Chardan Capital reaffirmed a “buy” rating and issued a $12.00 price target on shares of Taysha Gene Therapies in a report on Wednesday, November 5th. The Goldman Sachs Group set a $11.00 price objective on Taysha Gene Therapies in a research note on Thursday, December 4th. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $13.00 target price on shares of Taysha Gene Therapies in a research report on Friday, November 14th.

Taysha Gene Therapies Stock Performance

Shares of Taysha Gene Therapies stock opened at $5.25 on Monday. The business’s fifty day simple moving average is $4.91 and its 200 day simple moving average is $3.79. The company has a current ratio of 10.48, a quick ratio of 10.48 and a debt-to-equity ratio of 0.23. Taysha Gene Therapies has a 12 month low of $1.05 and a 12 month high of $6.02. The firm has a market capitalization of $1.44 billion, a P/E ratio of -15.91 and a beta of 1.02.

Taysha Gene Therapies (NASDAQ:TSHA) last announced its earnings results on Tuesday, November 4th. The company reported ($0.09) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.09). Taysha Gene Therapies had a negative return on equity of 67.26% and a negative net margin of 1,144.97%. As a group, analysts anticipate that Taysha Gene Therapies will post -0.35 EPS for the current year.

Insider Buying and Selling at Taysha Gene Therapies

In related news, insider Sukumar Nagendran sold 260,047 shares of Taysha Gene Therapies stock in a transaction dated Monday, December 1st. The stock was sold at an average price of $4.51, for a total value of $1,172,811.97. Following the completion of the sale, the insider owned 1,006,439 shares of the company’s stock, valued at approximately $4,539,039.89. This trade represents a 20.53% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders own 3.78% of the company’s stock.

Hedge Funds Weigh In On Taysha Gene Therapies

A number of institutional investors and hedge funds have recently added to or reduced their stakes in TSHA. ST Germain D J Co. Inc. raised its position in shares of Taysha Gene Therapies by 81.8% in the third quarter. ST Germain D J Co. Inc. now owns 9,633 shares of the company’s stock valued at $32,000 after purchasing an additional 4,333 shares during the period. Arrowpoint Investment Partners Singapore Pte. Ltd. purchased a new position in Taysha Gene Therapies in the 3rd quarter valued at approximately $40,000. Marex Group plc bought a new stake in Taysha Gene Therapies during the 2nd quarter valued at $29,000. E Fund Management Co. Ltd. purchased a new stake in shares of Taysha Gene Therapies during the second quarter worth $31,000. Finally, Allegheny Financial Group purchased a new stake in shares of Taysha Gene Therapies during the third quarter worth $49,000. Institutional investors own 77.70% of the company’s stock.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.